TCGA-BA-6869-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- TNFA_SIGNALING_VIA_NFKB+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- FATTY_ACID_METABOLISM+0.320
- P53_PATHWAY+0.310
- ADIPOGENESIS+0.270
- PEROXISOME+0.270
- XENOBIOTIC_METABOLISM+0.270
- BILE_ACID_METABOLISM+0.190
- CHOLESTEROL_HOMEOSTASIS+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- G2M_CHECKPOINT-0.440
- E2F_TARGETS-0.420
- UV_RESPONSE_DN-0.400
- MITOTIC_SPINDLE-0.290
- INTERFERON_GAMMA_RESPONSE-0.280
- KRAS_SIGNALING_UP-0.280
- TGF_BETA_SIGNALING-0.270
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UF-A7JF-01A-11R-A34R-07 | — | — | 0.864 |
| 2 | TCGA-86-8674-01A-21R-2403-07 | — | cohortA2 | 0.795 |
| 3 | SRR9879283 | — | cohortA1 | 0.764 |
| 4 | TCGA-GM-A5PV-01A-11R-A28M-07 | — | B | 0.759 |
| 5 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.732 |
| 6 | SRR1454803 | GTEX | — | 0.730 |
| 7 | 8f673a13-7f81-4685-a415-645ff6b5e2fb | — | — | 0.729 |
| 8 | SRR8943024 | — | — | 0.708 |
| 9 | TCGA-B6-A0IA-01A-11R-A034-07 | — | B | 0.707 |
| 10 | TCGA-OR-A5L3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.705 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |